Document is current
Any future updates will be listed below
-
Authors
Reynolds, John A.
Prattley, Jennifer
Geifman, Nophar
Lunt, Mark
Gordon, Caroline
Bruce, Ian N. https://orcid.org/0000-0003-3047-500X
,
-
Funding
Funding for this research was provided by:
Medical Research Council ((MR/M01665X/1))
- License Information
-
More Information
Article History
Received: 15 February 2021
Accepted: 10 July 2021
First Online: 29 July 2021
Declarations
:
: An anonymised dataset (with some data redacted to ensure anonymity of participants) was provided to the MASTERPLANS Consortium by UCB Biopharma SRL, Brussels; therefore, additional ethical approval was not required.
: Not applicable
: Professor Bruce reports grants from Versus Arthritis and the NIHR Manchester Biomedical Research Centre, grants and other from UCB, other from AstraZeneca, other from Medimmune and Merck Serono, grants from Genzyme Sanofi, other from Eli Lilly, other from Aurinia and other from ILTOO, outside the submitted work.Professor Gordon reports personal fees for honoraria from consultancy work from the Centre for Disease Control, MGP Sanofi and UCB; personal fees for speakers bureau from UCB; and an educational grant from UCB to Sandwell and West Birmingham NHS Trust that has supported her research work but was unrelated to any specific drug therapy.
